文献速递中毒与环境急症消化、代谢与肾脏急症

羟考酮与选择性5-羟色胺再摄取抑制剂联用相关的阿片类药物过量风险

Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.
PubMed 文献 · JAMA Netw Open · 2022-02-01
一句话结论服用帕罗西汀或氟西汀的患者起始羟考酮时阿片类药物过量风险小幅升高(校正HR 1.23,95%CI 1.06-1.31)。

该队列研究纳入2000年至2020年间3个美国健康保险数据库中正在接受SSRI治疗并起始羟考酮的成人,比较使用强效抑制CYP2D6的SSRI(氟西汀或帕罗西汀)与使用其他SSRI者的阿片类药物过量住院或急诊就诊率。共纳入2 037 490例,其中1 475 114例(72.4%)为女性,平均(SD)年龄50.1(15.3)岁;主要分析中观察到1035例过量事件(占队列0.05%)。使用抑制性SSRI者的阿片类药物过量校正发生率为9.47/1000人年,高于使用其他SSRI者的7.66/1000人年,校正HR为1.23(95%CI 1.06-1.31)。作者结论认为,在接受帕罗西汀或氟西汀治疗的患者中起始羟考酮与阿片类药物过量风险小幅增加相关。

要点

  • 正在服用帕罗西汀或氟西汀的患者起始羟考酮时,阿片类药物过量住院或急诊就诊的校正发生率为9.47/1000人年,高于服用其他SSRI者的7.66/1000人年。
  • 校正HR为1.23(95%CI 1.06-1.31),提示使用强效抑制CYP2D6的SSRI者阿片类药物过量风险小幅升高。
  • 主要分析中阿片类药物过量事件共1035例,占整个研究队列的0.05%。
  • 结果在多个亚组和敏感性分析中保持一致。

适用人群与场景

  • 2000年至2020年间,正在接受SSRI治疗并起始羟考酮的成人,数据来自3个美国健康保险数据库。

研究设计与关键结果

  • 研究类型为队列研究,纳入2 037 490例起始羟考酮时正在使用SSRI的患者,其中1 475 114例(72.4%)为女性,平均(SD)年龄50.1(15.3)岁。
  • 暴露为起始羟考酮时使用强效抑制CYP2D6的SSRI(氟西汀或帕罗西汀),对照为使用其他SSRI;1 418 712例(69.6%)起始羟考酮时使用的是其他SSRI。
  • 主要终点为起始羟考酮后365天内的阿片类药物过量住院或急诊就诊;主要分析中随访至停用羟考酮或停用索引SSRI组。
  • 主要分析观察到1035例过量事件(占研究队列0.05%);使用抑制性SSRI者的校正发生率为9.47/1000人年,使用其他SSRI者为7.66/1000人年,校正HR为1.23(95%CI 1.06-1.31)。
  • 结果在多个亚组和敏感性分析中保持一致。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在接受帕罗西汀或氟西汀治疗的患者中起始羟考酮与阿片类药物过量风险小幅增加相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Some selective serotonin reuptake inhibitors (SSRIs) inhibit the enzymes responsible for the metabolism of oxycodone, a potent prescription opioid. The clinical consequences of this interaction on the risk of opioid overdose have not been elucidated.

OBJECTIVE: To compare opioid overdose rates in patients initiating oxycodone while taking SSRIs that are potent inhibitors of the cytochrome-P450 2D6 enzyme (CYP2D6) vs SSRIs that are not.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study included adults who initiated oxycodone while receiving SSRI therapy between 2000 and 2020 whose data were included in 3 US health insurance databases.

EXPOSURES: Use of SSRIs that strongly inhibit CYP2D6 enzyme (fluoxetine or paroxetine) vs use of other SSRIs at the time of oxycodone initiation.

MAIN OUTCOMES AND MEASURES: Opioid overdose hospitalization or emergency department visit. Outcomes were assessed within 365 days of oxycodone initiation; in primary analyses, patients were followed up until the discontinuation of either oxycodone or their index SSRI group. Propensity score matching weights were used to adjust for confounding. Crude and weighted (adjusted) incidence rates and hazard ratios were estimated using Cox regression models, separately within each database and overall, stratifying on database.

RESULTS: A total of 2 037 490 initiated oxycodone while taking SSRIs (1 475 114 [72.4%] women; mean [SD] age, 50.1 [15.3] years). Most (1 418 712 [69.6%]) were receiving other SSRIs at the time of oxycodone initiation. In the primary analysis, we observed 1035 overdose events (0.05% of the study cohort). The adjusted incidence rate of opioid overdose in those using inhibiting SSRIs at the time of oxycodone initiation (9.47 per 1000 person-years) was higher than in those using other SSRIs (7.66 per 1000 person-years), indicating a greater risk of overdose among patients using CYP2D6-inhibiting SSRIs (adjusted hazard ratio, 1.23; 95% CI, 1.06-1.31). Results were consistent across multiple subgroup and sensitivity analyses.

CONCLUSIONS AND RELEVANCE: In this cohort study of US adults, initiating oxycodone in patients treated with paroxetine or fluoxetine was associated with a small increased risk of opioid overdose.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Yunusa I, Gagne JJ, Yoshida K, et al. Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors. JAMA Netw Open. 2022. PMID: 35201310. doi:10.1001/jamanetworkopen.2022.0194

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。